$INGN
Inogen Inc Stock $ingn

$ingn Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000095017023004370 Filed on February 24, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$72.16M	$88.09M	$377.2M
YoY Change	-10.23%	15.3%	5.37%
Cost Of Revenue	$41.43M	$58.62M	$223.7M
YoY Change	-8.7%	55.02%	23.24%
Gross Profit	$30.73M	$29.47M	$153.5M
YoY Change	-12.21%	-23.63%	-13.0%
Gross Profit Margin	42.59%	33.46%	40.7%
Selling, General & Admin	$47.30M	$29.87M	$164.7M
YoY Change	9.43%	-26.4%	10.0%
% of Gross Profit	153.92%	101.34%	107.26%
Research & Development	$5.344M	$5.934M	$21.94M
YoY Change	-0.37%	26.69%	150.41%
% of Gross Profit	17.39%	20.14%	14.29%
Depreciation & Amortization	$4.086M	$5.978M	$23.51M
YoY Change	-29.06%	3.66%	8.72%
% of Gross Profit	13.3%	20.28%	15.32%
Operating Expenses	$52.65M	$35.80M	$238.8M
YoY Change	8.35%	-20.91%	42.77%
Operating Profit	-$21.92M	-$6.328M	-$85.24M
YoY Change	61.31%	-5.17%	-1022.54%
Interest Expense	$1.525M	$1.715M	$2.837M
YoY Change	5158.62%	7695.45%	2099.22%
% of Operating Profit
Other Income/Expense, Net	$1.762M	$305.0K	$1.975M
YoY Change	-536.14%	-228.15%	-378.17%
Pretax Income	-$20.15M	-$56.47M	-$83.27M
YoY Change	44.05%	719.7%	-1061.64%
Income Tax	$196.0K	$141.0K	$504.0K
% Of Pretax Income
Net Earnings	-$20.35M	-$56.61M	-$83.77M
YoY Change	43.16%	147.45%	1222.79%
Net Earnings / Revenue	-28.2%	-64.26%	-22.21%
Basic Earnings Per Share	-$0.88		-$3.67
Diluted Earnings Per Share	-$0.88	-$2.47	-$3.67
COMMON SHARES
Basic Shares Outstanding	22.97M	22.92M	22.85M
Diluted Shares Outstanding	23.01M		22.85M

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$174.6M	$187.0M	$187.0M
YoY Change	-21.86%	-23.83%	-23.83%
Cash & Equivalents	$164.1M	$187.0M	$187.0M
Short-Term Investments	$10.43M	$0.00	$0.00
Other Short-Term Assets	$14.02M	$19.19M	$19.19M
YoY Change	-44.46%	-26.22%	-26.22%
Inventory	$38.82M	$34.09M	$34.09M
Prepaid Expenses
Receivables	$53.89M	$62.73M	$62.73M
Other Receivables	$1.859M	$1.626M	$1.626M
Total Short-Term Assets	$283.1M	$304.6M	$304.6M
YoY Change	-10.99%	-7.46%	-7.46%
LONG-TERM ASSETS
Property, Plant & Equipment	$45.94M	$43.27M	$64.92M
YoY Change	16.81%	11.16%	1.7%
Goodwill	$32.89M	$32.85M
YoY Change	-0.14%	-0.39%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.590M	$2.445M	$2.445M
YoY Change	20.41%	-27.3%	-27.3%
Total Long-Term Assets	$102.5M	$100.4M	$100.4M
YoY Change	-34.49%	-37.38%	-37.38%
TOTAL ASSETS
Total Short-Term Assets	$283.1M	$304.6M	$304.6M
Total Long-Term Assets	$102.5M	$100.4M	$100.4M
Total Assets	$385.7M	$405.0M	$405.0M
YoY Change	-18.74%	-17.26%	-17.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$18.04M	$18.24M	$29.07M
YoY Change	-0.36%	77.78%	183.43%
Accrued Expenses	$19.78M	$19.61M	$19.61M
YoY Change	22.35%	-17.08%	-17.08%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$63.38M	$65.35M	$65.35M
YoY Change	5.94%	6.24%	6.24%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$41.00M	$42.29M	$42.29M
YoY Change	-27.45%	-26.81%	-26.81%
Total Long-Term Liabilities	$41.00M	$42.29M	$42.29M
YoY Change	-27.45%	-26.81%	-26.81%
TOTAL LIABILITIES
Total Short-Term Liabilities	$63.38M	$65.35M	$65.35M
Total Long-Term Liabilities	$41.00M	$42.29M	$42.29M
Total Liabilities	$104.4M	$107.6M	$107.6M
YoY Change	-10.28%	-9.77%	-9.77%
SHAREHOLDERS EQUITY
Retained Earnings	-$34.85M	-$14.50M
YoY Change	-163.3%	-120.93%
Common Stock	$316.2M	$312.1M
YoY Change	4.67%	4.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$281.3M	$297.4M	$297.4M
YoY Change
Total Liabilities & Shareholders Equity	$385.7M	$405.0M	$405.0M
YoY Change	-18.74%	-17.26%	-17.26%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$20.35M	-$56.61M	-$83.77M
YoY Change	43.16%	147.45%	1222.79%
Depreciation, Depletion And Amortization	$4.086M	$5.978M	$23.51M
YoY Change	-29.06%	3.66%	8.72%
Cash From Operating Activities	-$6.301M	-$15.48M	-$37.53M
YoY Change	-65.18%	-338.26%	-258.81%
INVESTING ACTIVITIES
Capital Expenditures	$1.076M	$7.132M	$3.337M
YoY Change	-21.23%	-219.42%	-39.13%
Acquisitions
YoY Change
Other Investing Activities	-$10.30M	$188.0K	$10.35M
YoY Change	-11419.78%	-102.94%	9.8%
Cash From Investing Activities	-$17.11M	-$6.944M	-$10.88M
YoY Change	322.26%	-43.9%	-25.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	559.0K	-112.0K	380.0K
YoY Change	-617.59%	273.33%	-97.47%
NET CHANGE
Cash From Operating Activities	-6.301M	-15.48M	-37.53M
Cash From Investing Activities	-17.11M	-6.944M	-10.88M
Cash From Financing Activities	559.0K	-112.0K	380.0K
Net Change In Cash	-22.88M	-22.54M	-48.51M
YoY Change	3.4%	281.42%	-305.88%
FREE CASH FLOW
Cash From Operating Activities	-$6.301M	-$15.48M	-$37.53M
Capital Expenditures	$1.076M	$7.132M	$3.337M
Free Cash Flow	-$7.377M	-$22.61M	-$40.87M
YoY Change	-62.1%	-281.35%	-325.16%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001294133
CY2022	us-gaap	Derivative Remaining Maturity1 DerivativeRemainingMaturity1	P1M
CY2022	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grant In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodFairValue	0
CY2021	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grant In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodFairValue	0
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grant In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodFairValue	0
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-36309
CY2022	dei	Entity Registrant Name EntityRegistrantName	INOGEN, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	33-0989359
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	301 Coromar Drive
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Goleta
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	93117
CY2022	dei	City Area Code CityAreaCode	(805)
CY2022	dei	Local Phone Number LocalPhoneNumber	562-0500
CY2022	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2022	dei	Trading Symbol TradingSymbol	INGN
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	310500000
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	22969574
CY2022	dei	Auditor Firm AuditorFirmId	34
CY2022	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2022	dei	Auditor Location AuditorLocation	Los Angeles, California, USA
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	187014000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	235524000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	9989000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	62725000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	24452000
CY2022Q4	us-gaap	Inventory Net InventoryNet	34093000
CY2021Q4	us-gaap	Inventory Net InventoryNet	31873000
CY2022Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	1626000
CY2021Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	1343000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19187000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	26005000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	304645000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	329186000
CY2022Q4	ingn	Rental Equipment Net Of Allowances RentalEquipmentNetOfAllowances	61679000
CY2021Q4	ingn	Rental Equipment Net Of Allowances RentalEquipmentNetOfAllowances	59073000
CY2022Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	11497000
CY2021Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	12050000
CY2022Q4	ingn	Computer Equipment And Software Gross ComputerEquipmentAndSoftwareGross	9559000
CY2021Q4	ingn	Computer Equipment And Software Gross ComputerEquipmentAndSoftwareGross	8585000
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	3197000
CY2021Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	3167000
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	6126000
CY2021Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	5956000
CY2022Q4	ingn	Land And Building LandAndBuilding	125000
CY2021Q4	ingn	Land And Building LandAndBuilding	125000
CY2022Q4	ingn	Construction In Process ConstructionInProcess	2930000
CY2021Q4	ingn	Construction In Process ConstructionInProcess	1639000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	95113000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	90595000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	51844000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	51669000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	43269000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	38926000
CY2022Q4	us-gaap	Goodwill Goodwill	32852000
CY2021Q4	us-gaap	Goodwill Goodwill	32979000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	177000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	60147000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21653000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24912000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2445000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3363000
CY2022Q4	us-gaap	Assets Assets	405041000
CY2021Q4	us-gaap	Assets Assets	489513000
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	33974000
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	25689000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11190000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17307000
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	7790000
CY2021Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	6480000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3515000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3393000
CY2022Q4	ingn	Contract With Customer Liability And Lease Deferred Revenue Current ContractWithCustomerLiabilityAndLeaseDeferredRevenueCurrent	8880000
CY2021Q4	ingn	Contract With Customer Liability And Lease Deferred Revenue Current ContractWithCustomerLiabilityAndLeaseDeferredRevenueCurrent	8568000
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	75000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	65349000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	61512000
CY2022Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	12123000
CY2021Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	7246000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	19764000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	23281000
CY2021Q4	ingn	Earnout Liability Noncurrent EarnoutLiabilityNoncurrent	15386000
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	10399000
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	11861000
CY2022Q4	us-gaap	Liabilities Liabilities	107635000
CY2021Q4	us-gaap	Liabilities Liabilities	119286000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22941643
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22941643
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22731586
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22731586
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	23000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	23000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	312126000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	299463000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-14500000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	69272000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-243000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1469000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	297406000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	370227000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	405041000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	489513000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	320549000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	311730000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	280189000
CY2022	ingn	Rental Revenue Net RentalRevenueNet	56692000
CY2021	ingn	Rental Revenue Net RentalRevenueNet	46273000
CY2020	ingn	Rental Revenue Net RentalRevenueNet	28298000
CY2022	us-gaap	Revenues Revenues	377241000
CY2021	us-gaap	Revenues Revenues	358003000
CY2020	us-gaap	Revenues Revenues	308487000
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	197805000
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	161824000
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	156764000
CY2022	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	11103000
CY2021	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	8860000
CY2020	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	5695000
CY2022	ingn	Cost Of Rental CostOfRental	25903000
CY2021	ingn	Cost Of Rental CostOfRental	19696000
CY2020	ingn	Cost Of Rental CostOfRental	13543000
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	223708000
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	181520000
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	170307000
CY2022	ingn	Gross Profit Sales Revenue GrossProfitSalesRevenue	122744000
CY2021	ingn	Gross Profit Sales Revenue GrossProfitSalesRevenue	149906000
CY2020	ingn	Gross Profit Sales Revenue GrossProfitSalesRevenue	123425000
CY2022	ingn	Gross Profit Rental Revenue GrossProfitRentalRevenue	30789000
CY2021	ingn	Gross Profit Rental Revenue GrossProfitRentalRevenue	26577000
CY2020	ingn	Gross Profit Rental Revenue GrossProfitRentalRevenue	14755000
CY2022	us-gaap	Gross Profit GrossProfit	153533000
CY2021	us-gaap	Gross Profit GrossProfit	176483000
CY2020	us-gaap	Gross Profit GrossProfit	138180000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21943000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16576000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14080000
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	120767000
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	112815000
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	97520000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	43905000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-83772000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	549000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	37852000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	38605000
CY2022	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-52161000
CY2022	us-gaap	Operating Expenses OperatingExpenses	238776000
CY2021	us-gaap	Operating Expenses OperatingExpenses	167243000
CY2020	us-gaap	Operating Expenses OperatingExpenses	150205000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-85243000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	9240000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-12025000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	2837000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	129000
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	909000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-862000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-710000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5836000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1975000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-581000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6745000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-83268000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	8659000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5280000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	504000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	14992000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-6333000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-5829000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-597000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-800000
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	857000
CY2022	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	-3130000
CY2021	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	1746000
CY2020	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	-82000
CY2022	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	-1990000
CY2021	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	-47000
CY2020	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	207000
CY2022	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-1140000
CY2021	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	1793000
CY2020	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-289000
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	25000
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1000
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-6000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1712000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	994000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	562000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-85484000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5339000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5267000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.67
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.67
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22852571
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22490027
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21980326
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22852571
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22490027
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21980326
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	344621000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8203000
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2084000
CY2020	ingn	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	19000
CY2020	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	331000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	332000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-5829000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	562000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	349623000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10943000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1948000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1691000
CY2021	ingn	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	412000
CY2021	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	235000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13699000
CY2022	ingn	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	1252000
CY2022	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	103000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-6333000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-83772000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-6333000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	370227000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12283000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	44000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-83772000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1712000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	994000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	297406000
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-1141000
CY2020	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	319000
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3395000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-5829000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	23514000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	21628000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	18581000
CY2022	ingn	Gain Loss On Write Off Of Rental Assets And Other Fixed Assets GainLossOnWriteOffOfRentalAssetsAndOtherFixedAssets	-3095000
CY2021	ingn	Gain Loss On Write Off Of Rental Assets And Other Fixed Assets GainLossOnWriteOffOfRentalAssetsAndOtherFixedAssets	-1521000
CY2020	ingn	Gain Loss On Write Off Of Rental Assets And Other Fixed Assets GainLossOnWriteOffOfRentalAssetsAndOtherFixedAssets	-864000
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	154000
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	65000
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	94000
CY2022	ingn	Provision For Sales Returns And Doubtful Accounts ProvisionForSalesReturnsAndDoubtfulAccounts	13024000
CY2021	ingn	Provision For Sales Returns And Doubtful Accounts ProvisionForSalesReturnsAndDoubtfulAccounts	11094000
CY2020	ingn	Provision For Sales Returns And Doubtful Accounts ProvisionForSalesReturnsAndDoubtfulAccounts	10486000
CY2020	ingn	Health Care Organization Patient Service Revenue Adjustments HealthCareOrganizationPatientServiceRevenueAdjustments	2579000
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	2423000
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	2062000
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	1283000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	12283000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	10943000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	8203000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	14444000
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-82000
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-15386000
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-11596000
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1053000
CY2022	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-52161000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	51337000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6127000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8177000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5601000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	10775000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-7591000
CY2022	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	281000
CY2021	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-705000
CY2020	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-928000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-6803000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8104000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-31000
CY2022	ingn	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-3259000
CY2021	ingn	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	16087000
CY2020	ingn	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	2970000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-224000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-96000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-2296000
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6759000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6476000
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	16668000
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-5830000
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-6106000
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	10231000
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	870000
CY2022	ingn	Increase Decrease In Warranty Reserve IncreaseDecreaseInWarrantyReserve	6187000
CY2021	ingn	Increase Decrease In Warranty Reserve IncreaseDecreaseInWarrantyReserve	-668000
CY2020	ingn	Increase Decrease In Warranty Reserve IncreaseDecreaseInWarrantyReserve	1823000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1150000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	1613000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-203000
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-82000
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	3291000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	499000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37532000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	23633000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	37013000
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	9987000
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	22751000
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	10014000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	19256000
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	14545000
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	132000
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	255000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3337000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5482000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4385000
CY2022	ingn	Payments To Produce And Purchase Rental Equipment PaymentsToProduceAndPurchaseRentalEquipment	17885000
CY2021	ingn	Payments To Produce And Purchase Rental Equipment PaymentsToProduceAndPurchaseRentalEquipment	18453000
CY2020	ingn	Payments To Produce And Purchase Rental Equipment PaymentsToProduceAndPurchaseRentalEquipment	12957000
CY2022	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	331000
CY2021	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	153000
CY2020	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	163000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10877000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14645000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25640000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	44000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	13699000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	332000
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1691000
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1948000
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2084000
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1355000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	647000
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	350000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	380000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15000000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2066000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-481000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-426000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	486000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-48510000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	23562000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	13925000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	235524000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	211962000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	198037000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	187014000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	235524000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	211962000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	428000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1544000
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-713000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	353000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	55000
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1. Nature of business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Inogen, Inc. (Company or Inogen) was incorporated in Delaware on November 27, 2001. The Company is a medical technology company that primarily develops, manufactures and markets innovative portable oxygen concentrators (POCs) used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Traditionally, these patients have relied on stationary oxygen concentrator systems for use in the home and oxygen tanks or cylinders for mobile use, which the Company calls the delivery model. The tanks and cylinders must be delivered regularly and have a finite amount of oxygen, which requires patients to plan activities outside of their homes around delivery schedules and a finite oxygen supply. Additionally, patients must attach long, cumbersome tubing to their stationary concentrators simply to enable mobility within their homes. The Company’s proprietary Inogen One</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:"Times New Roman", serif;min-width:fit-content;">®</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a single battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. The Company’s Inogen One systems reduce the patient’s reliance on stationary concentrators and scheduled deliveries of tanks with a finite supply of oxygen, thereby improving patient quality of life and fostering mobility.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company incorporated Inogen Europe Holding B.V., a Dutch limited liability company, on </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">April 13, 2017</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">. On May 4, 2017, Inogen Europe Holding B.V. acquired all issued and outstanding capital stock of MedSupport Systems B.V. (MedSupport) and began operating under the name Inogen Europe B.V. The Company merged Inogen Europe Holding B.V. and Inogen Europe B.V. on December 28, 2018. Inogen Europe B.V. is the remaining legal entity. Inogen completed the acquisition of New Aera, Inc. (New Aera) on August 9, 2019.</span></p>
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Accounting estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, warranty reserves and expense, determining the stand-alone selling price (SSP) and service period of performance obligations, rental asset valuations and write-downs, accounts receivable allowances for bad debts, returns and adjustments, impairment of long-lived assets, stock-based compensation expense, income taxes, fair value of acquired intangible assets and goodwill and fair value of earnout liabilities. Actual results could differ from these estimates.</span></p>
CY2022	ingn	Standard Warranty Period Offered StandardWarrantyPeriodOffered	P3Y
CY2022	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	6598000
CY2021	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	5866000
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	5156000
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	6764000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	320549000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	311730000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	280189000
CY2021Q4	ingn	Deferred Capped Rental Revenue DeferredCappedRentalRevenue	0
CY2022Q4	ingn	Deferred Capped Rental Revenue DeferredCappedRentalRevenue	0
CY2022	ingn	Rental Revenue Recognition New Accounting Pronouncement Timing RentalRevenueRecognitionNewAccountingPronouncementTiming	P30D
CY2022	us-gaap	Standard Product Warranty Description StandardProductWarrantyDescription	The Company generally provides a warranty against defects in material and workmanship. The Company provides a 3-year, 5-year or lifetime warranty on Inogen One systems sold and a 3-year and lifetime warranty on Inogen At Home systems sold. The Company only offers a lifetime warranty for direct-to-consumer sales of its oxygen concentrators.
CY2022	us-gaap	Derivatives Methods Of Accounting Hedging Derivatives DerivativesMethodsOfAccountingHedgingDerivatives	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Fair value of derivative instruments and hedging activities</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company transacts business in foreign currencies and has international sales and expenses denominated in foreign currencies, subjecting the Company to foreign currency risk. The Company has entered into foreign currency forward contracts, generally with maturities of twelve months or less, to reduce the volatility of cash flows, primarily related to forecasted revenue denominated in certain foreign currencies. These contracts allow the Company to sell Euros in exchange for U.S. dollars at specified contract rates. Forward contracts are used to hedge forecasted sales over specific months. Changes in the fair value of these forward contracts designed as cash flow and balance sheet hedges are recorded as a component of accumulated other comprehensive income within stockholders’ equity and are recognized in the consolidated statements of comprehensive loss during the period which approximates the time the corresponding sales occur. The Company may also enter into foreign exchange contracts that are not designated as hedging instruments for financial accounting purposes. These contracts are generally entered into to offset the gains and losses on certain asset and liability balances until the expected time of repayment. Accordingly, any gains or losses resulting from changes in the fair value of the non-designated contracts are reported in other income (expense), net in the consolidated statements of comprehensive loss. The gains and losses on these contracts generally offset the gains and losses associated with the underlying foreign currency-denominated balances, which are also reported in other income (expense), net.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company records the assets or liabilities associated with derivative instruments and hedging activities at fair value based on Level 2 inputs in other current assets or other current liabilities, respectively, in the consolidated balance sheet. The Company had a related payable of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">422</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> and a related receivable of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">1,671</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">December 31, 2022 and 2021, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company documents the hedging relationship and its risk management objective and strategy for undertaking the hedge, the hedging instrument, the hedged transaction, the nature of the risk being hedged, how the hedging instrument’s effectiveness in offsetting the hedged risk will be assessed prospectively and retrospectively, and a description of the method used to measure ineffectiveness. The Company assesses hedge effectiveness and ineffectiveness at a minimum quarterly but may assess it monthly. For derivative instruments that are designed and qualify as part of a cash flow hedging relationship, the effective portion of the gain or loss on the derivative is reported in other comprehensive loss and reclassified into earnings in the same periods during which the hedged transaction affects earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current period earnings.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Company will discontinue hedge accounting prospectively when it determines that the derivative is no longer effective in offsetting cash flows attributable to the hedge risk. The cash flow hedge is de-designated because a forecasted transaction is not probable of occurring, or management determines to remove the designation of the cash flow hedge. In all situations in which hedge accounting is discontinued and the derivative remains outstanding, the Company continues to carry the derivative at its fair value on the balance sheet and recognizes any subsequent changes in the fair value in earnings. When it is probable that a forecasted transaction will not occur, the Company will discontinue hedge accounting and recognize immediately in earnings gains and losses that were accumulated in other comprehensive loss related to the hedging relationship.</span></p>
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1712000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	994000
CY2022	ingn	Preacquisition Loss Recoveries PreacquisitionLossRecoveries	0
CY2021	ingn	Preacquisition Loss Recoveries PreacquisitionLossRecoveries	630000
CY2022Q4	us-gaap	Cash Cash	27970000
CY2021Q4	us-gaap	Cash Cash	48817000
CY2022Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	113534000
CY2021Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	186707000
CY2022Q4	us-gaap	Asset Backed Securities At Carrying Value AssetBackedSecuritiesAtCarryingValue	6474000
CY2022Q4	us-gaap	Us Government Securities At Carrying Value USGovernmentSecuritiesAtCarryingValue	18939000
CY2022Q4	ingn	Institutional Insured Liquidity Deposit Savings InstitutionalInsuredLiquidityDepositSavings	20097000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	187014000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	235524000
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	9989000
CY2022	ingn	Increase Decrease In Net Rental Revenue IncreaseDecreaseInNetRentalRevenue	1483000
CY2021	ingn	Increase Decrease In Net Rental Revenue IncreaseDecreaseInNetRentalRevenue	877000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	62725000
CY2022	ingn	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable Net HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivableNet	1.000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	24452000
CY2021	ingn	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable Net HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivableNet	1.000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	62725000
CY2022	ingn	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable Net HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivableNet	1.000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	24452000
CY2021	ingn	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable Net HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivableNet	1.000
CY2021	ingn	Percentage Of Non Us Revenue Invoiced In Euros PercentageOfNonUSRevenueInvoicedInEuros	0.741
CY2020	ingn	Percentage Of Non Us Revenue Invoiced In Euros PercentageOfNonUSRevenueInvoicedInEuros	0.736
CY2022Q4	ingn	Doubtful Accounts DoubtfulAccounts	77000
CY2022	ingn	Doubtful Accounts Percentage DoubtfulAccountsPercentage	0.001
CY2021Q4	ingn	Doubtful Accounts DoubtfulAccounts	52000
CY2021	ingn	Doubtful Accounts Percentage DoubtfulAccountsPercentage	0.002
CY2022Q4	ingn	Allowances For Sales Returns AllowancesForSalesReturns	483000
CY2022	ingn	Sales Returns Percentage SalesReturnsPercentage	0.008
CY2021Q4	ingn	Allowances For Sales Returns AllowancesForSalesReturns	810000
CY2021	ingn	Sales Returns Percentage SalesReturnsPercentage	0.031
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	560000
CY2022	ingn	Allowance For Doubtful Accounts Receivable Current Percentage AllowanceForDoubtfulAccountsReceivableCurrentPercentage	0.009
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	862000
CY2021	ingn	Allowance For Doubtful Accounts Receivable Current Percentage AllowanceForDoubtfulAccountsReceivableCurrentPercentage	0.033
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;">Concentration of credit risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. At times, cash account balances may be in excess of the amounts insured by the Federal Deposit Insurance Corporation. However, management believes the risk of loss to be minimal. The Company performs periodic evaluations of the relative credit standing of these institutions and has not experienced any losses on its cash and cash equivalents to date. The Company has also entered into hedging relationships with a single counterparty to offset the forecasted Euro-based revenues. The credit risk has been reduced due to a net settlement arrangement whereby the Company is allowed to net settle transactions with a single net amount payable by one party to the other.</span></p>
CY2022	ingn	Percentage Of Non Us Revenue Invoiced In Euros PercentageOfNonUSRevenueInvoicedInEuros	0.709
CY2022	us-gaap	Revenues Revenues	377241000
CY2021	us-gaap	Revenues Revenues	358003000
CY2020	us-gaap	Revenues Revenues	308487000
CY2022	ingn	Transfer Of Inventory To Rental Equipment TransferOfInventoryToRentalEquipment	1221000
CY2021	ingn	Transfer Of Inventory To Rental Equipment TransferOfInventoryToRentalEquipment	906000
CY2020	ingn	Transfer Of Inventory To Rental Equipment TransferOfInventoryToRentalEquipment	1970000
CY2022Q4	us-gaap	Inventory Work In Process And Raw Materials InventoryWorkInProcessAndRawMaterials	26496000
CY2021Q4	us-gaap	Inventory Work In Process And Raw Materials InventoryWorkInProcessAndRawMaterials	21909000
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	9324000
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	12116000
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1727000
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2152000
CY2022Q4	us-gaap	Inventory Net InventoryNet	34093000
CY2021Q4	us-gaap	Inventory Net InventoryNet	31873000
CY2022Q4	us-gaap	Property Plant And Equipment Salvage Value PropertyPlantAndEquipmentSalvageValue	0
CY2022	us-gaap	Cost Of Property Repairs And Maintenance CostOfPropertyRepairsAndMaintenance	4528000
CY2021	us-gaap	Cost Of Property Repairs And Maintenance CostOfPropertyRepairsAndMaintenance	3387000
CY2020	us-gaap	Cost Of Property Repairs And Maintenance CostOfPropertyRepairsAndMaintenance	2527000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	15045000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	12853000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9577000
CY2022Q4	ingn	Rental Equipment Allowance RentalEquipmentAllowance	2255000
CY2021Q4	ingn	Rental Equipment Allowance RentalEquipmentAllowance	1290000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	95113000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	90595000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	51844000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	51669000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	43269000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	38926000
CY2022	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-52161000
CY2022	ingn	Fair Value Of Earnout Benefit FairValueOfEarnoutBenefit	13687000
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2022	us-gaap	Advertising Expense AdvertisingExpense	33265000
CY2021	us-gaap	Advertising Expense AdvertisingExpense	35183000
CY2020	us-gaap	Advertising Expense AdvertisingExpense	34180000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-83772000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-6333000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-5829000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22852571
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22490027
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21980326
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22852571
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22490027
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21980326
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.67
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.67
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22852571
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22490027
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21980326
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	115155
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	166258
CY2020	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	64471
CY2022	ingn	Weighted Average Number Of Diluted Shares Outstanding Based On Net Loss WeightedAverageNumberOfDilutedSharesOutstandingBasedOnNetLoss	22967726
CY2021	ingn	Weighted Average Number Of Diluted Shares Outstanding Based On Net Loss WeightedAverageNumberOfDilutedSharesOutstandingBasedOnNetLoss	22656285
CY2020	ingn	Weighted Average Number Of Diluted Shares Outstanding Based On Net Loss WeightedAverageNumberOfDilutedSharesOutstandingBasedOnNetLoss	22044797
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	857984
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	318581
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	760173
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	177000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	84564000
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2020Q4	us-gaap	Goodwill Goodwill	33165000
CY2021	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	186000
CY2021Q4	us-gaap	Goodwill Goodwill	32979000
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	127000
CY2022Q4	us-gaap	Goodwill Goodwill	32852000
CY2022Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8469000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8775000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	9004000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6239000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6062000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	60147000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	24417000
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	3133000
CY2021Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	2894000
CY2022Q4	ingn	Accrued Employee Stock Purchase Plan Deductions AccruedEmployeeStockPurchasePlanDeductions	470000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	87000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	67000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	19000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	4000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	177000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	18237000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10258000
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	10837000
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	12488000
CY2022Q4	ingn	Accrued Purchasing Card Liability AccruedPurchasingCardLiability	2606000
CY2021Q4	ingn	Accrued Purchasing Card Liability AccruedPurchasingCardLiability	1488000
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	492000
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	486000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1802000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	969000
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	33974000
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	25689000
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	2620000
CY2021Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	8274000
CY2022Q4	ingn	Accrued Wages And Other Payroll Related Items Current AccruedWagesAndOtherPayrollRelatedItemsCurrent	4967000
CY2021Q4	ingn	Accrued Wages And Other Payroll Related Items Current AccruedWagesAndOtherPayrollRelatedItemsCurrent	5469000
CY2021Q4	ingn	Accrued Employee Stock Purchase Plan Deductions AccruedEmployeeStockPurchasePlanDeductions	670000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11190000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17307000
CY2022	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	options to extend the leases for up to 5 years.
CY2022	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2022	ingn	Rent Expense Including Short Term Lease Cost RentExpenseIncludingShortTermLeaseCost	3870000
CY2021	ingn	Rent Expense Including Short Term Lease Cost RentExpenseIncludingShortTermLeaseCost	4095000
CY2020	ingn	Rent Expense Including Short Term Lease Cost RentExpenseIncludingShortTermLeaseCost	2864000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	3964000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	3319000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	3828000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	3854000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	225000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	19417000
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M18D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.029
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.029
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths	3974000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Two LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo	3683000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Three LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree	2718000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Four LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour	2708000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive	2745000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Rolling Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive	9355000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	25183000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1904000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	23279000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3515000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	19764000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	23279000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-84422000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	7621000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-6464000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	1154000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	1038000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	1184000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-83268000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	8659000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5280000
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-74000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	201000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	271000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	198000
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	303000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	266000
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	381000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	504000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	537000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	505000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	10263000
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	309000
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	4194000
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-193000
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-22000
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-72000
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	14435000
CY2020	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	44000
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	20000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	504000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	14992000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	549000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	10600000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	10575000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	27824000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	21138000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	2784000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	2668000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4042000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2665000
CY2022Q4	ingn	Deferred Tax Assets Intangible Amortization DeferredTaxAssetsIntangibleAmortization	2045000
CY2022Q4	ingn	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	5674000
CY2021Q4	ingn	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	6507000
CY2022Q4	ingn	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	2915000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	55884000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	43553000
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	8674000
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	7664000
CY2021Q4	ingn	Deferred Tax Liabilities Intangible Amortization DeferredTaxLiabilitiesIntangibleAmortization	12389000
CY2022Q4	ingn	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	5277000
CY2021Q4	ingn	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	6077000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	13951000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	26130000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	41933000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17423000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0353
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0139
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0386
CY2022	ingn	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Expense Benefit EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationExpenseBenefit	-0.0102
CY2021	ingn	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Expense Benefit EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationExpenseBenefit	-0.2172
CY2020	ingn	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Expense Benefit EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationExpenseBenefit	-0.1680
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.0132
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0595
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0811
CY2022	ingn	Effective Income Tax Rate Reconciliation Change In Fair Value EffectiveIncomeTaxRateReconciliationChangeInFairValue	-0.0388
CY2021	ingn	Effective Income Tax Rate Reconciliation Change In Fair Value EffectiveIncomeTaxRateReconciliationChangeInFairValue	0.2819
CY2020	ingn	Effective Income Tax Rate Reconciliation Change In Fair Value EffectiveIncomeTaxRateReconciliationChangeInFairValue	0.0419
CY2022	ingn	Effective Income Tax Rate Reconciliation Nondeductible Compensation EffectiveIncomeTaxRateReconciliationNondeductibleCompensation	-0.0150
CY2021	ingn	Effective Income Tax Rate Reconciliation Nondeductible Compensation EffectiveIncomeTaxRateReconciliationNondeductibleCompensation	0.0704
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2775
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	2.0169
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0007
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0063
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0157
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0061
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	1.7311
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.1039
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17423000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	41933000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	24510000
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	2366000
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	2078000
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1932000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2078000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1932000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1889000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	242000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	146000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	70000
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	181000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	46000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	154000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2366000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2078000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1932000
CY2022Q3	ingn	Corporate Minimum Income Tax Rate CorporateMinimumIncomeTaxRate	0.15
CY2022	ingn	Voting Rights Associated With Each Share Of Common Stock VotingRightsAssociatedWithEachShareOfCommonStock	1
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	0
CY2022	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	0
CY2020	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	0
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	980884
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	35.24
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y10M2D
CY2019	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Per Share ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValuePerShare	34.07
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	18626
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	17.81
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	6779
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	48.23
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	955479
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	35.49
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y10M6D
CY2020	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Per Share ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValuePerShare	11.81
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	955479
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	35.49
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P1Y10M6D
CY2020Q4	ingn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested And Exercisable Per Share Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedAndExercisablePerShareAverageIntrinsicValue	11.81
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	955479
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	35.49
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P1Y10M6D
CY2020Q4	ingn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested And Expected To Vest Per Share Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedAndExpectedToVestPerShareAverageIntrinsicValue	11.81
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	955479
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	35.49
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y10M6D
CY2020	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Per Share ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValuePerShare	11.81
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	486038
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	28.19
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	10000
CY2021	ingn	Share Based Compensation Arrangement By Share Based Payment Award Per Share Price Forfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardPerSharePriceForfeited	83.30
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	83.30
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	459441
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	42.18
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y4M9D
CY2021	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Per Share ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValuePerShare	4.31
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	459441
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	42.18
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P1Y4M9D
CY2021Q4	ingn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested And Exercisable Per Share Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedAndExercisablePerShareAverageIntrinsicValue	4.31
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	459441
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	42.18
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P1Y4M9D
CY2021Q4	ingn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested And Expected To Vest Per Share Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedAndExpectedToVestPerShareAverageIntrinsicValue	4.31
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	459441
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	42.18
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y4M9D
CY2021	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Per Share ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValuePerShare	4.31
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	14154
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.14
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	15417
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	43.27
CY2022	ingn	Stock Issued During Period Shares Stock Options Expired StockIssuedDuringPeriodSharesStockOptionsExpired	81586
CY2022	ingn	Share Based Compensation Arrangements By Share Based Payment Award Options Expired In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice	40.08
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	348284
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	44.21
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P0Y5M4D
CY2022	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value Per Share ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValuePerShare	2.07
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	348284
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	44.21
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P0Y5M4D
CY2022Q4	ingn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested And Exercisable Per Share Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedAndExercisablePerShareAverageIntrinsicValue	2.07
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	348284
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	44.21
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P0Y5M4D
CY2022Q4	ingn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Vested And Expected To Vest Per Share Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsVestedAndExpectedToVestPerShareAverageIntrinsicValue	2.07
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	309000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	14524000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	494000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12283000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10943000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8203000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12283000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10943000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8203000
CY2022Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	109900000
CY2021Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	13726000
CY2020Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	14394000
CY2019Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	12571000
CY2022	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	10416000
CY2021	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	9168000
CY2020	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	9462000
CY2022	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	8234000
CY2021	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	-597000
CY2020	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	-754000
CY2022	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	12463000
CY2021	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	9239000
CY2020	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	6885000
CY2022Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	19913000
CY2021Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	13726000
CY2020Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	14394000
CY2022	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	8234000
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-1140000
CY2021	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	1793000
CY2020	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-289000
CY2022Q4	ingn	Number Of Contract Ineffective Hedges NumberOfContractIneffectiveHedges	3
CY2021Q4	ingn	Number Of Contract Ineffective Hedges NumberOfContractIneffectiveHedges	0
CY2020Q4	ingn	Number Of Contract Ineffective Hedges NumberOfContractIneffectiveHedges	0
CY2022Q4	ingn	Number Of Contract Designated Hedges NumberOfContractDesignatedHedges	0
CY2022Q4	ingn	Number Of Contract Non Designated Hedges NumberOfContractNonDesignatedHedges	3
CY2021Q4	ingn	Number Of Contract Designated Hedges NumberOfContractDesignatedHedges	13
CY2021Q4	ingn	Number Of Contract Non Designated Hedges NumberOfContractNonDesignatedHedges	2

Files In Submission

Name	View Source	Status
0000950170-23-004370-index-headers.html	Edgar Link	pending
0000950170-23-004370-index.html	Edgar Link	pending
0000950170-23-004370.txt	Edgar Link	pending
0000950170-23-004370-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img251433502_0.jpg	Edgar Link	pending
ingn-20221231.htm	Edgar Link	pending
ingn-20221231.xsd	Edgar Link	pending
ingn-ex23_1.htm	Edgar Link	pending
ingn-ex31_1.htm	Edgar Link	pending
ingn-ex31_2.htm	Edgar Link	pending
ingn-ex32_1.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ingn-20221231_cal.xml	Edgar Link	unprocessable
ingn-20221231_def.xml	Edgar Link	unprocessable
ingn-20221231_lab.xml	Edgar Link	unprocessable
ingn-20221231_pre.xml	Edgar Link	unprocessable
ingn-20221231_htm.xml	Edgar Link	completed
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INGN
Inogen Inc Stock $ingn

2023 Q1 Form 10-K Financial Statement

#000095017023004370 Filed on February 24, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INGN Inogen Inc Stock $ingn

2023 Q1 Form 10-K Financial Statement

#000095017023004370 Filed on February 24, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INGN
Inogen Inc Stock $ingn